HASTINGS PAUL J — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

HASTINGS PAUL J has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $59K.

Profile

HASTINGS PAUL J

Paul J Hastings is listed as the Chief Executive Officer of Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. As of the most recent SEC filing dated 2026-01-08, he is the primary executive officer with Nkarta and has no reported insider purchases or sales in that filing.

RoleInsider
Notability62/100
LinksWikipedia

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-06-22NKTXNkarta, Inc.S — Open-market sale1.8K$2.71$5K
2026-01-20NKTXNkarta, Inc.S — Open-market sale26.0K$2.07$54K
2026-01-08NKTXNkarta, Inc.A — Grant or award94.0K$0.00

Companies — Last 90 Days

Frequently Asked Questions

Who is HASTINGS PAUL J?

Paul J Hastings is listed as the Chief Executive Officer of Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. As of the most recent SEC filing dated 2026-01-08, he is the primary executive officer with Nkarta and has no reported insider purchases or sales in that filing.…

How many SEC Form 4 filings has HASTINGS PAUL J submitted recently?

2 primary Form 4 filings in the last 90 days, covering 2 companies.

Has HASTINGS PAUL J been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 2 open-market sales ($59K) across all tracked filings.

Where can I see all of HASTINGS PAUL J's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live HASTINGS PAUL J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.